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Aims The Global Registry of Acute Coronary Events (GRACE) score was developed to evaluate risk in patients with
myocardial infarction. However, its performance in type 2 myocardial infarction is uncertain.
...................................................................................................................................................................................................
Methods and
results
In two cohorts of consecutive patients with suspected acute coronary syndrome from 10 hospitals in Scotland
(n= 48 282) and a tertiary care hospital in Sweden (n= 22 589), we calculated the GRACE 2.0 score to estimate
death at 1 year. Discrimination was evaluated by the area under the receiver operating curve (AUC), and com-
pared for those with an adjudicated diagnosis of type 1 and type 2 myocardial infarction using DeLong’s test. Type
1 myocardial infarction was diagnosed in 4981 (10%) and 1080 (5%) patients in Scotland and Sweden, respectively.
At 1 year, 720 (15%) and 112 (10%) patients died with an AUC for the GRACE 2.0 score of 0.83 [95% confidence
interval (CI) 0.82–0.85] and 0.85 (95% CI 0.81–0.89). Type 2 myocardial infarction occurred in 1121 (2%) and 247
(1%) patients in Scotland and Sweden, respectively, with 258 (23%) and 57 (23%) deaths at 1 year. The AUC was
0.73 (95% CI 0.70–0.77) and 0.73 (95% CI 0.66–0.81) in type 2 myocardial infarction, which was lower than for
type 1 myocardial infarction in both cohorts (P< 0.001 and P= 0.008, respectively).
...................................................................................................................................................................................................
Conclusion The GRACE 2.0 score provided good discrimination for all-cause death at 1 year in patients with type 1 myocardial
infarction, and moderate discrimination for those with type 2 myocardial infarction.
...................................................................................................................................................................................................
Trial registration ClinicalTrials.gov number, NCT01852123.
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Introduction
Coronary heart disease is responsible for around 2 million deaths
across Europe every year.1 To improve prognostication and promote
consistency in the investigation and management of patients with
acute coronary syndrome, the Global Registry of Acute Coronary
Events (GRACE) score was developed.2–5 The score applies clinical
variables, the electrocardiogram, and cardiac biomarkers to estimate
risk of future all-cause mortality and myocardial infarction. The use of
the GRACE 2.0 score in patients with non-ST-segment elevation
acute coronary syndrome has a class Ia recommendation for guiding
prognosis and IIa recommendation for guiding management across all
international guidelines.6–8
Since the introduction of the GRACE score, there have been sig-
nificant changes in the way we diagnose myocardial infarction, driven
by major improvements in the sensitivity of cardiac troponin. The
Fourth Universal Definition of Myocardial Infarction recommends
the use of high-sensitivity cardiac troponin (hs-cTn) assays and a sex-
specific 99th centile diagnostic threshold for myocardial injury and in-
farction.9 These assays have the ability to quantify myocardial injury
at a threshold 10-fold lower than was in use at the time of the original
GRACE study. This increase in diagnostic sensitivity has led to an
understanding that myocardial infarction can occur in a number of
different clinical settings.10–12
The Fourth Universal Definition recognizes myocardial infarction
may occur due to atheromatous plaque rupture and thrombosis
(type 1 myocardial infarction), or secondary to an imbalance in myo-
cardial oxygen supply or demand without coronary atherothrombo-
sis (type 2 myocardial infarction).9 Patients with type 2 myocardial
infarction are older and more often have comorbidities and are at
higher risk of adverse outcomes with as few as 30% of patients alive
at 5 years.13 Despite a significant increase in risk of non-
cardiovascular death, patients with type 2 myocardial infarction ap-
pear to have a similar risk of future cardiovascular events as those
with type 1 myocardial infarction.14 To date, there are no validated
prognostic tools to estimate all-cause mortality or future cardiovas-
cular events in this population. Our aim was to evaluate the perform-
ance of the GRACE 2.0 score for the prediction of all-cause death in
patients with type 1 and type 2 myocardial infarction.
Methods
Study populations
We assessed the performance of the GRACE 2.0 score in two cohorts of
consecutive patients presenting to the Emergency Department with sus-
pected acute coronary syndrome in Scotland and in Sweden.
High-Sensitivity Troponin in the Evaluation of patients with suspected
Acute Coronary Syndrome (High-STEACS) is a stepped-wedge cluster
randomized controlled trial to evaluate implementation of a hs-cTnI assay
in consecutive patients with suspected acute coronary syndrome across
10 hospitals in Scotland.15 Troponin was measured using the Abbott
ARCHITECTSTAT high-sensitive troponin I assay (Abbott Diagnostics,
Chicago, IL, USA). This assay has an inter-assay coefficient of variation of
<10% at 4.7 ng/L and a 99th centile of 16 ng/L in women and 34 ng/L in
men.16 All patients attending the Emergency Department between June
2013 and March 2016 were identified as having suspected acute coronary
syndrome by the attending clinician at the time troponin was requested,
using an electronic form integrated into the clinical care pathway. Patients
were excluded if they had been admitted previously during the trial
period or were not resident in Scotland. We used regional and national
registries to ensure complete follow-up for the trial population with out-
come events adjudicated by a panel.
The study population from the Karolinska University Hospital in
Stockholm was derived from an observational cohort study of all patients
>25 years old with a visit to the Emergency Department with chest pain
and at least one hs-cTn measurement from January 2011 to October
2014.17,18 Troponin was measured using the Roche Elecsys hs-cTnT assay
(Roche Diagnostics, Mannheim, Germany). This assay has a limit of detec-
tion of 5 ng/L, and a limit of blank of 3 ng/L. The 99th percentile cut-off
point is 14 ng/L, and the coefficient of variation is <10% at 13 ng/L. The
hospital’s local administrative database was used to identify eligible
patients. Patients were excluded if they had an estimated glomerular fil-
tration rate of <15 mL/min/1.73 m2. The obtained data, together with la-
boratory data, were sent to the Swedish National Board of Health and
Welfare who linked information on comorbidities and outcomes, use of
medication, and dates and causes of death from the National Patient
Register, the Prescribed Drug Register, and the Cause-of-Death register,
respectively. The Patient Register has nationwide coverage on diagnoses
at discharge and surgical procedures coded according to the International
Classification of Disease. Details of study approvals are contained in the
Supplementary material online.
Adjudication of myocardial infarction and
outcomes
All diagnoses were adjudicated in accordance with the Fourth Universal
Definition of Myocardial Infarction.9 In both cohorts, two physicians inde-
pendently reviewed all clinical information with discordant diagnoses
resolved by a third reviewer (Scotland) or by consensus discussion
(Sweden). Type 1 myocardial infarction was defined in those with sus-
pected acute coronary syndrome with symptoms or signs of myocardial
ischaemia on the electrocardiogram and evidence of myocardial necrosis:
hs-cTnI concentration above the sex-specific 99th centile with a rise and/
or fall in concentration where serial testing was performed (Scotland);
hs-cTnT concentration above the uniform 99th centile with a delta of
3 ng/L (Sweden). Patients with myocardial necrosis, symptoms or signs of
myocardial ischaemia, and evidence of increased myocardial oxygen de-
mand or decreased supply secondary to an alternative condition without
evidence of acute atherothrombosis were defined as type 2 myocardial
infarction. Patients with hs-cTn concentrations above the 99th centile
without symptoms or signs of myocardial ischaemia were classified as
having myocardial injury. All non-ischaemic myocardial injury was classi-
fied as acute, unless a change of <_20% was observed on serial testing,9 or
the final adjudicated diagnosis was chronic heart failure or chronic renal
failure, where the classification was chronic myocardial injury.
The primary outcome was all-cause death at 1 year, and the secondary
outcome was all-cause death or type 1 myocardial infarction at 1 year. All
in-hospital and community deaths are recorded on the National General
Register of Scotland, and the Swedish Patient Register. Subsequent myo-
cardial infarction events were identified through the electronic patient re-
cord in Scotland with adjudication as for the index diagnosis, and using
ICD-10 coding (I21 and I22) from the Swedish Patient Register in the
Swedish cohort.
Statistical analysis
Baseline characteristics were summarized for each cohort and in groups
by according to adjudicated diagnosis. Group-wise comparisons were
performed using v2, Kruskal–Wallis, or one-way analysis of variance tests
as appropriate. We determined the GRACE 2.0 score for all-cause death,
2 J. Hung et al.
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and for all-cause death or type 1 myocardial infarction at 1 year. This
score includes age, heart rate, systolic blood pressure, creatinine as con-
tinuous variables, with categorical variables for Killip class, cardiac arrest
at admission, ST-segment deviation, and elevated cardiac biomarkers
(defined here as any hs-cTn concentration above the 99th centile).
Where data were missing within the Scottish cohort, this was assumed to
be at random, and we applied multiple imputation using chained equa-
tions with five imputations of the dataset. For imputation, we applied
Bayesian linear regression models for continuous data (creatinine, heart
rate, and systolic blood pressure), multinomial logistic regression for or-
dinal data (Killip class) and logistic regression for binary data (e.g. cardiac
arrest status). We assessed overall GRACE 2.0 model discrimination by
determining the area under the receiver operating curve (AUC) and
compared performance in patients with type 1 and type 2 myocardial in-
farction using the DeLong method. We assessed model calibration both
graphically, and by using the Hosmer–Lemeshow goodness of fit test. In
addition, we assessed GRACE performance by evaluating previously
defined categories of mortality risk (<3% low, >_3 and <_8% intermediate
and >8% high risk) using the Kaplan–Meier method. We explored the im-
pact of multiple imputation by performing a sensitivity analysis in which
we evaluated the complete dataset only. These results were similar to
the primary analysis and are presented in the Supplementary material on-
line, Table S1. In post hoc analyses, we also determined performance of
the GRACE 2.0 score for in-hospital death and of hs-cTn alone to predict
all-cause death at 1 year. All analyses were performed in R (Version 3.5.1)
and the code required to calculate the GRACE 2.0 score is available in
Supplementary material online, Appendix S1.
Results
Study populations
The Scottish cohort consisted of 48 282 consecutive patients
(61 ± 17 years, 47% women) with suspected acute coronary syn-
drome of whom 10 360 (21%) had hs-cTnI concentrations above the
99th centile. It was possible to adjudicate the diagnosis in 88% (9115/
10 360) of patients. The final diagnosis was type 1 myocardial infarc-
tion in 55% (4981/9115), type 2 myocardial infarction in 12% (1121/
9115), and acute or chronic myocardial injury in 18% (1676/9115)
and 14% (1287/9115), respectively. The remainder of patients had
type 4a (9/9115) or 4b (41/9115) myocardial infarction.
The Swedish cohort consisted of 22 589 consecutive patients with
suspected acute coronary syndrome of whom 3853 (17%) patients
had hs-cTnT concentrations above the 99th centile. The final diagno-
sis was type 1 myocardial infarction in 28% (1080/3853) of patients,
and type 2 myocardial infarction in 6% (247/3853), with acute or
chronic myocardial injury in 30% (1144/3853) and 35% (1347/3853),
respectively.
Patient characteristics
Compared to patients with a diagnosis of type 1 myocardial infarc-
tion, those with type 2 myocardial infarction were older (74 ± 14 vs.
68± 14 years), more likely to be women (55% vs. 40%), and more
likely to have a history of cardiovascular disease. Similar differences
were apparent in both cohorts (Table 1). Patients with type 2 myo-
cardial infarction were less likely to be offered coronary angiography,
revascularization or secondary prevention than those with type 1
myocardial infarction (Table 2). There were differences in the covari-
ates which influence the GRACE 2.0 score between groups, with
higher heart rates (101 vs. 77 b.p.m.), lower systolic blood pressures
(130 vs. 141 mmHg) and a higher proportion of patients with
increased Killip class observed in those with type 2 myocardial infarc-
tion (Table 3).
GRACE risk score and prediction of
death at 1 year
We obtained follow-up in 100% of participants for primary and
secondary outcomes at 1 year. In patients with type 1 myocardial
infarction, 15% (720/4981) and 10% (112/1080) died from any
cause at 1 year in the Scottish and Swedish cohorts, respectively.
The GRACE 2.0 score was higher in those with type 2 compared
to type 1 myocardial infarction across both cohorts (Table 3) and
had good discriminative ability with an AUC of 0.83 [95% confi-
dence interval (CI) 0.82–0.85] and 0.85 (95% CI 0.81–0.89), re-
spectively (Figure 1).
In patients with type 2 myocardial infarction, 23% (258/1121) and
23% (57/247) died from any cause at 1 year in the Scottish and
Swedish cohorts, respectively. The GRACE 2.0 score had moderate
discriminative ability, with an AUC of 0.73 (95% CI 0.70–0.77) and
0.73 (95% CI 0.66–0.81), respectively, and performed less well than
in patients with type 1 myocardial infarction (DeLong test, P< 0.001
and P= 0.008 vs. type 1 myocardial infarction in Scottish and Swedish
cohorts, respectively, Figure 1).
Similar performance was observed in men and women with type
1 and type 2 myocardial infarction in both cohorts (Supplementary
material online, Table S3). Calibration plots and the Hosmer–
Lemeshow test indicated the GRACE 2.0 score underestimated fu-
ture all-cause death across all deciles of risk in both type 1 and
type 2 myocardial infarction (Figure 2, Supplementary material on-
line, Table S2).
GRACE risk categories
In the Scottish cohort, we evaluated conventional GRACE categories
of low, intermediate, and high predicted risk of mortality. Observed
event rates were higher in patients with type 2 myocardial infarction
who had a low or intermediate predicted risk of death (Figure 3).
Baseline demographic information was similar across all categories of
risk irrespective of the diagnosis of type 1 and type 2 myocardial in-
farction (Supplementary material online, Table S4). In patients with
type 2 myocardial infarction in the Scottish cohort at low risk of
death, there were fewer new prescription for aspirin (25% vs. 67%),
statin (11% vs. 56%), angiotensin-converting enzyme inhibitor or
angiotensin II receptor blocker (15% vs. 49%) compared to those
with type 1 myocardial infarction. Similar patterns were observed in
patients at intermediate or high risk of death.
GRACE score and prediction of death or
myocardial infarction
In patients with type 1 myocardial infarction, a total of 22% (1075/
4981) and 16% (173/1080) of patients died or had a myocardial in-
farction at 1 year in the Scottish and Swedish cohorts, respectively.
The AUC for the GRACE 2.0 model incorporating death or future
myocardial infarction was 0.76 (95% CI 0.74–0.77) and 0.81 (95% CI
0.77–0.85), respectively.
Performance of the GRACE 2.0 score 3
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Table 1 Characteristics of the Scottish and Swedish cohorts of patients diagnosed with type 1 and type 2 myocardial
infarction
Scottish cohort Swedish cohort
All
patients
Type 1 myocardial
infarction
Type 2 myocardial
infarction
All
patients
Type 1 myocardial
infarction
Type 2 myocardial
infarction
Number of participants 48 282 4981 1121 22 589 1080 247
Age (years), mean (SD) 61 (17) 68 (14) 74 (14) 56 (17) 69 (13) 72 (13)
Men, n (%) 25 720 (53) 2995 (60) 501 (45) 11 817 (52) 743 (69) 122 (49)
Past medical history, n (%)
Myocardial infarction 4214 (9) 667 (13) 163 (15) 1885 (8) 184 (17) 47 (19)
Ischaemic heart disease 11 912 (25) 1519 (30)a 454 (40) 2570 (11)b — —
Cerebrovascular disease 2949 (6) 368 (7) 135 (12) 940 (4) 66 (6) 20 (8)
Diabetes mellitus 3518 (7) 802 (16) 147 (13) 2191 (10) 204 (19) 54 (22)
Heart failure hospitalization 4322 (9) 792 (16) 292 (26) 1244 (6) 86 (8) 40 (16)
Previous revascularization, n (%)
Previous PCI or CABG 4464 (9) 592 (12) 129 (12) 1979 (9) 210 (19) 53 (22)
Medications at presentation, n (%)
Aspirin 13 163 (27) 1694 (34) 471 (42) 4258 (19) 414 (38) 101 (41)
Statin 19 366 (40) 2377 (48) 632 (56) 4265 (19) 362 (34) 86 (35)
ACE inhibitor or ARB 15 618 (32) 1995 (40) 514 (46) 5547 (25) 456 (42) 130 (53)
Beta-blocker 13 173 (27) 1598 (32) 489 (44) 5508 (24) 441 (41) 140 (57)
Oral anti-coagulantc 3253 (7) 292 (6) 170 (15) — — —
Electrocardiogramd
Myocardial ischaemia — 1872 (38) 383 (34) — 281 (26) 67 (27)
Physiological parametersd
Heart rate (b.p.m.) — 79 (20) 105 (35) — 76 (17) 94 (31)
Systolic blood pressure (mmHg) — 142 (28) 132 (30) — 153 (28) 142 (34)
Haematology and clinical chemistry
Haemoglobin (g/L) 136 (22) 136 (22) 126 (29) — 139 (17) 130 (20)
eGFR (mL/min) 54 (13) 51 (14) 46 (15) 88 (23) 74 (23) 66 (25)
Peak hs-cTnI (ng/L) 4 (2–16) 855 (104–6775) 125 (48–604) — — —
Peak hs-cTnT (ng/L) — — — — 182 (49–616) 77 (32–173)
eGFR calculated according to the MDRD equation (mL/min).
aDefined as prior angina, myocardial infarction, or revascularization.
bDefined as prior myocardial infarction or revascularization.
c,dElectrocardiogram findings and physiological parameters provided for patients with myocardial infarction only.
.............................................................................. ............................................................................
....................................................................................................................................................................................................................
Table 2 Rates of angiography, revascularization, and prescription for medical therapy on discharge in the Scottish and
Swedish cohorts
Scottish cohort Swedish cohort
Type 1 myocardial
infarction (n5 4981)
Type 2 myocardial
infarction (n5 1121)
Type 1 myocardial
infarction (n51064)
Type 2 myocardial
infarction (n5228)
Coronary angiographya 3083 (62) 123 (11) — —
PCI or CABGa 2217 (45) 24 (2) 543 (51) 7 (3)
Aspirin 3934 (79) 588 (52) 918 (86) 101 (44)
P2Y12 inhibitor 3544 (71) 319 (28) 871 (82) 26 (11)
ACE or ARB 3572 (72) 618 (55) 725 (68) 118 (52)
Beta-blocker 3476 (70) 708 (63) 169 (74) 946 (89)
Statin therapy 4141 (83) 700 (62) 883 (83) 92 (40)
Information from the Swedish cohort available in 99% (1064/1080) with type 1 and 92% (228/247) with type 2 myocardial infarction.
Values are number (%).
aAngiography and revascularization within 30 days of presentation P< 0.001 for all treatments in patients with type 1 vs. type 2 across both cohorts. P-values obtained from
group-wise comparisons using v2 test.
4 J. Hung et al.
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..In patients with type 2 myocardial infarction, there were 27%
(297/1121) and 26% (63/247) deaths or myocardial infarctions at 1
year. Here, the GRACE 2.0 score gave an AUC of 0.70 (95% CI 0.67–
0.74) and 0.72 (95% CI 0.65–0.80), respectively (P= 0.007 and
P= 0.042 vs. type 1 myocardial infarction). Calibration plots showed
the GRACE 2.0 model underestimated future risk in type 1 and type
2 myocardial infarction across both cohorts (Supplementary material
online, Figure S1).
Post hoc analysis
In a post hoc analysis, the GRACE 2.0 score had better discrimination
for in-hospital death in patients with type 1 compared to type 2
............................................................... ...............................................................
......................................................................................................................................................................................................................
Table 3 Components of the GRACE 2.0 risk score in patients with type 1 and type 2 myocardial infarction
Type 1 myocardial infarction Type 2 myocardial infarction
Scottish cohort Swedish cohort Scottish cohort Swedish cohort
Age 68 (14) 69 (13) 74 (14) 72 (13)
Heart rate (b.p.m.) 77 (65–92) 73 (64–84) 101 (81–125) 89 (72–109)
Systolic blood pressure (mmHg) 141 (123–160) 152 (135–170) 130 (111–150) 140 (120–160)
Creatinine 0.93 (0.80–1.19) 0.93 (0.79–1.13) 1.05 (0.82–1.39) 0.98 (0.78–1.27)
Killip class (%)
I 4419 (88.7) 1014 (93.9) 852 (76) 188 (76.1)
II 279 (5.6) 64 (5.9) 126 (11.2) 51 (20.6)
III 205 (4.1) 2 (0.2) 130 (11.6) 8 (3.3)
IV 78 (1.6) 0 (0.0) 13 (1.6) 0 (0.0)
Cardiac arrest (%) 278 (5.6) 8 (0.1) 30 (2.7) 1 (0.4)
Troponin >99th centile at presentation (%) 4092 (82.2) 929 (86.0) 881 (78.6) 199 (80.6)
ECG ischaemia (%) 1627 (32.7) 281 (26.0) 311 (27.7) 67 (27.1)
STEMI (%) 915 (18.4) 0 (0) 5 (0.5) 0 (0)
GRACE 2.0 risk of death at 1 year (%) 4.9% (2.3–11.7%) 3.8% (1.9–8.2%) 11.2% (5.4–22.1%) 7.7% (3.5–19.9%)
GRACE 2.0 risk of death or MI at 1 year (%) 9.4% (5.6–18.2%) 7.7% (4.9–14.0%) 17.8% (10.2–29%) 13.3% (7.4–25.9%)
Values are represented as mean (SD) or median (IQR).
Figure 1 Comparison of the discrimination of the GRACE score for the prediction of all-cause mortality in patients with type 1 (red) and type 2
(blue) myocardial infarction using the area under the receiver operator characteristic curve, in the Scottish and Swedish cohorts.
Performance of the GRACE 2.0 score 5
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..myocardial infarction, where performance was moderate
(Supplementary material online, Table S5). When applied as a con-
tinuous variable, both hs-cTnI and hs-cTnT were moderate predic-
tors of all-cause death at 1 year (Supplementary material online,
Table S6).
Discussion
We evaluated the performance of the GRACE 2.0 score for the pre-
diction of all-cause death, and all-cause death or myocardial infarction
in consecutive patients with type 1 and type 2 myocardial infarction
from two independent cohorts across two countries. We observe
that the GRACE 2.0 score provides good discrimination for all-cause
death in patients with type 1 myocardial infarction diagnosed using
hs-cTn assays and for both cardiac troponin I and T. Consistent with
the original validation study,4 discrimination for all-cause death was
better than for death or myocardial infarction. In patients with type 2
myocardial infarction, the GRACE 2.0 score provided moderate dis-
crimination in the prediction of all-cause death and performed less
well in the prediction of all-cause death or myocardial infarction. As
the GRACE 2.0 score performed better in patients with type 1 myo-
cardial infarction, there may be opportunities to develop a bespoke
model for risk prediction in patients with type 2 myocardial
infarction.
The GRACE 2.0 score was derived prior to the publication of the
first Universal Definition of Myocardial Infarction,19 which introduced
a classification based on the underlying mechanism. Whilst type 1
myocardial infarction is caused exclusively by atherosclerotic plaque
rupture and thrombotic coronary artery occlusion, type 2 myocardial
infarction is a heterogeneous condition, occurring due to an
imbalance in myocardial oxygen supply or an unmet need in myocar-
dial oxygen demand in the context of another acute illness. A type 2
myocardial infarction may occur due to coronary pathology such as
vasospasm, spontaneous dissection or coronary embolism, or with
bystander stable coronary artery disease or normal coronary arteries
in the context of tachyarrhythmia, severe hypoxia or hypotension.
Whilst we have a strong evidence base for treatments which reduce
all-cause mortality and future cardiovascular events in patients with
type 1 myocardial infarction, at present, we have no guidelines to sup-
port investigation or management of patients with type 2 myocardial
infarction, and in these patients clinical outcomes are worse, with as
few as 30% of patients alive at 5 years.20–25
We recently demonstrated future cardiovascular risk was
increased in all patients with myocardial injury and infarction, irre-
spective of diagnostic classification, despite a vast excess in non-
cardiovascular death in patients without type 1 myocardial infarction.
Patients with type 2 myocardial infarction were at almost four-fold
increased risk of cardiovascular events relative to those without myo-
cardial injury. This risk appears to be highest in those with a history of
prior coronary artery disease, suggesting underlying coronary ather-
oma may at least in part be driving future cardiovascular risk.26,27 In
order to identify patients with type 2 myocardial infarction who may
benefit from further investigation and treatment, accurate risk stratifi-
cation is required.
In this analysis, we demonstrate the GRACE 2.0 score performed
well in the prediction of all-cause mortality and future cardiovascular
events in patients with type 1 myocardial infarction, but discrimin-
ation was lower in those with type 2 myocardial infarction. At the
time the GRACE was derived, the diagnosis of myocardial infarction
was based on contemporary cardiac biomarkers with a diagnostic
threshold at least 10-fold higher than advocated in current
Figure 2 Evaluation of the calibration of the GRACE score for the prediction of all-cause mortality in patients with type 1 (red) and type 2 (blue)
myocardial infarction, using the observed rate of events vs. the predicted rate of events, in the Scottish and Swedish cohorts. Each dot represents one
decile of risk.
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..guidelines.9 The subsequent increase in sensitivity of cardiac troponin
led to a reduction in the diagnostic threshold, and an increase in the
recognition of myocardial injury and infarction in other conditions.14
A number of studies indicate a phenotypic distinction between
patients with type 1 and type 2 myocardial infarction.14,20–28 Those
with type 2 myocardial infarction are older, more often female, with
lower haemoglobin and impairment in renal function. The GRACE
2.0 score was not derived in these patients, and although we found its
performance to be acceptable with an AUC of 0.72 for all-cause
death, it is perhaps not surprising it performed less well when com-
pared with type 1 myocardial infarction.
Some attempts have been made to derive risk stratification tools
in patients with type 2 myocardial infarction. The TARRACO risk
score was derived in 611 patients with type 2 myocardial infarction
and myocardial injury.27 This score applies troponin concentrations
from a contemporary sensitive assay and the covariates age, hyper-
tension, dyspnoea, anaemia, and the absence of chest pain and had
moderate discrimination for future major adverse cardiovascular
events (AUC 0.74, 95% CI 0.70–0.79). However, in a recent direct
comparison of the GRACE, TIMI, and TARRACO scores in 359
patients with type 2 myocardial infarction from a single tertiary
cardiac centre, only the GRACE score was predictive of all-cause
mortality at 90 days (AUC 0.70, 95% CI 0.63–0.77), performing
better than the bespoke TARRACO score (AUC 0.52, 95% CI 0.46–
0.58).28
Analysis of the calibration of the GRACE 2.0 model in type 1 and
type 2 myocardial infarction identified underestimation of risk across
all outcomes. This likely reflects differences between the population
of consented patients recruited into the GRACE registry, and the
consecutive patient cohort evaluated here. There are a number of
potentially important comorbidities not included in the GRACE 2.0
score which are common in clinical practice and could influence sur-
vival, particularly in those with type 2 myocardial infarction. These in-
clude atrial fibrillation, chronic obstructive pulmonary disease, heart
failure, malignancy, dementia, and frailty. Furthermore, as suggested
in a post hoc analysis, incorporating troponin concentration as a con-
tinuous variable could offer improved performance. Whether the in-
clusion of absolute troponin concentration, comorbidities or
additional covariates, such as haemoglobin concentration, could im-
prove model performance requires exploration.
Figure 3 Comparison of survival free from death in patients with type 1 and type 2 myocardial infarction grouped by GRACE risk category (low
risk <3%, green; intermediate risk >_3 and <8%, orange; high risk >_8%, red) in the Scottish cohort only.
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Given the implementation of hs-cTn assays has been shown to in-
crease recognition and the prevalence of type 2 myocardial infarc-
tion, there is an urgent and unmet need to improve risk prediction in
these patients. Until bespoke risk prediction tools are available for
patients with type 2 myocardial infarction, the GRACE 2.0 allows
identification of patients at increased risk of death, both in-hospital
and at 1 year. This may be helpful to guide clinicians when reviewing
patients with type 2 myocardial infarction and deciding who may
benefit from more intensive monitoring or further investigation for
underlying coronary disease. We observed lower prescription rates
for secondary prevention therapy in patients with type 2 myocardial
infarction. This was most evident in those classified by GRACE as
low- or intermediate risk, where rates of prescriptions for new anti-
platelet or statin therapies in type 2 myocardial infarction were half
those of type 1 myocardial infarction, and outcomes were worse. In
those classified as high risk, prescription rates and outcomes between
patients with type 1 and type 2 myocardial infarction were similar.
Whether secondary prevention therapy in patients with type 2 myo-
cardial infarction will improve clinical outcomes requires evaluation
in prospective trials.14
We acknowledge some limitations. Firstly, whilst the GRACE 2.0
score was derived and validated across 14 countries, we only evalu-
ate performance in Scotland and Sweden. However, we included
consecutive patients across two different healthcare systems using
different high-sensitivity troponin assays and found consistent results.
The consistency in results was evident despite differences in the ori-
ginal study design and in the selection of patients between the two
healthcare sites. Second, whilst we adjudicated all diagnoses
according to the latest Fourth Universal Definition of Myocardial
Infarction using all available clinical information, we acknowledge that
diagnostic misclassification is possible. In the Scottish cohort where
there was consensus amongst the adjudication panel that there was
insufficient clinical information to make a definitive diagnosis, because
of missing admission or discharge letters, we did not attempt to adju-
dicate the diagnosis. Third, where information on covariates required
for calculating the GRACE score was missing this was determined to
be at random, and to minimize bias we applied multiple imputation.
As data were missing in patients with type 1 and type 2 myocardial in-
farction in equal proportion, and we observed consistent perform-
ance in a sensitivity analysis restricted to the dataset where complete
case data were available, we do not think this impacted on the results
observed. Fourth, we acknowledge that our analysis of in-hospital
events was post hoc and is limited by a small number of events. Finally,
we acknowledge that the rates of coronary angiography were lower
here than in other registries or clinical trials of selected patient popu-
lations.29,30 We enrolled all consecutive patients in both cohorts,
where older patients with comorbidities managed out with the cor-
onary care unit were included rather than excluded. This improves
the generalizability of our findings, and whilst angiography is not
required for the diagnosis of myocardial infarction, lower rates may
have contributed to diagnostic misclassification and influenced per-
formance of the GRACE 2.0 score.
The GRACE 2.0 score provided good discrimination for all-cause
death at 1 year in patients with type 1 myocardial infarction, and
moderate discrimination for those with type 2 myocardial infarction.
Until specific risk prediction tools are derived and validated, clinicians
Take home figure Performance of the GRACE 2.0 score in patients with type 1 and type 2 myocardial infarction.
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.
should consider applying the GRACE 2.0 score to guide prognosis
and subsequent management in patients with type 2 myocardial
infarction.
Supplementary material
Supplementary material is available at European Heart Journal online.
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